NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics IRVINE, Calif. & AMSTERDAM--Agendia®, Inc., a leader in precision oncology for breast cancer, Read More
Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Multicenter study of over 1000 females with breast cancer, published in npj Breast Cancer, finds that genomic risk and molecular subtype, and not race, drives differential survival outcomes IRVINE, Calif., and AMSTERDAM — March Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Read More
Newsroom
News, Stories & Breast Cancer Blog
For Breast Cancer Patients, Genomic Tests Enable Personalized Treatment Options
Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make personalized care decisions. For the more than 300,000 women diagnosed with breast cancer Read More
Early Breast Cancer: Personalizing Chemotherapy Decisions
Using real-world data from the FLEX registry, MammaPrint, a 70-gene signature for risk of distant recurrence, was found to be predictive of chemotherapy benefit and distant recurrence-free interval prognosis in early-stage breast cancer. Read More
SABCS25: Agendia’s Genomic Testing Guides Breast Cancer Care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer. Agendia, a precision oncology company focused on early-stage breast Read More
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhD Title: Leveraging real-world evidence to personalize adjuvant therapy Read More
Mapping Your Path: How Genomic Testing Can Personalize Your Breast Cancer Treatment Plan
Genomic testing can help personalize your breast cancer treatment plan by helping map a path ahead. When navigating a breast cancer diagnosis, it can feel like approaching one fork in the road after another. Read More
Test May Predict Breast Cancer Recurrence Risk, Chemotherapy Benefit
For patients with HR+, HER2- early breast cancer, MammaPrint may predict distant recurrence-free interval prognosis and chemotherapy benefit.Key TakeawaysMammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer.High-risk patients benefit significantly Read More
Understanding Predictive vs. Prognostic Breast Cancer Genomic Testing
What Does Your Breast Cancer Genomic Test Really Tell You— and Why MammaPrint’s Latest Data Matters? If you or someone you love has been diagnosed with early-stage breast cancer, especially HR-positive/ HER2-negative breast cancer, Read More
